Lantheus Holdings, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings
Lantheus Holdings, Inc. (LNTH) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 · last filed 2024-02-22
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2023-09-30 was $0.00.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2022 was $9.30M, a 365.00% increase from fiscal 2021.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2021 was $2.00M.
- Lantheus Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2020 was -$1.20M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | $8.20M derived: sum of 4 quarters · filed 2024-02-22 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | $8.20M derived: sum of 3 quarters · filed 2024-02-22 | $7.70M derived: sum of 4 quarters · filed 2024-02-22 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $8.20M derived: sum of 2 quarters · filed 2024-02-22 | $7.70M derived: sum of 3 quarters · filed 2024-02-22 | $8.90M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-12-31 | $8.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $7.70M derived: sum of 2 quarters · filed 2024-02-22 | $8.90M derived: sum of 3 quarters · filed 2024-02-22 | $9.30M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $700.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.10M 10-Q · filed 2023-11-02 | $5.60M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.60M 10-Q · filed 2023-08-03 | $6.10M derived: sum of 3 quarters · filed 2023-08-03 | $5.70M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $400.00K 10-Q · filed 2023-05-04 | $4.90M derived: sum of 2 quarters · filed 2023-05-04 | $4.50M derived: sum of 3 quarters · filed 2023-05-04 | $3.30M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $4.10M derived: sum of 2 quarters · filed 2023-02-23 | $2.90M derived: sum of 3 quarters · filed 2023-02-23 | $2.00M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$1.60M derived: sum of 2 quarters · filed 2022-11-03 | -$2.50M 10-Q · filed 2022-11-03 | -$3.60M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$2.10M 10-Q · filed 2022-08-04 | -$3.20M derived: sum of 3 quarters · filed 2022-08-04 | -$3.30M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$900.00K 10-Q · filed 2022-04-29 | -$2.00M derived: sum of 2 quarters · filed 2022-04-29 | -$2.10M derived: sum of 3 quarters · filed 2022-04-29 | |
| 2020-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$1.20M derived: sum of 2 quarters · filed 2022-02-24 | -$1.20M 10-K · filed 2022-02-24 | |
| 2020-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$100.00K 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |